AI and Pharma Jobs – Asrar Qureshi’s Blog Post #1229

AI and Pharma Jobs – Asrar Qureshi’s Blog Post #1229

Dear Colleagues! This is Asrar Qureshi’s Blog Post #1229 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here.

Credit: Polina Tankilevich

Credit: Tima Miroshnichenko

Preamble

This blog post is based on a recent article published in Pharma Voice. Link at the end.

AI, Jobs, and the Future of Pharma: What Leaders Should Know

Artificial intelligence has become one of the most talked-about forces shaping the future of work. From viral Super Bowl commercials to boardroom strategy sessions, AI is everywhere, promising productivity gains, faster innovation, and disruptive change. But alongside that excitement, there’s a growing fear: Will AI replace our jobs?

In sectors like retail and tech, most notably at companies such as Amazon, recent layoffs have been large, with hundreds of thousands of jobs cut in the name of “AI efficiency.” That has sparked real anxiety across industries about automation wiping out human roles.

For the pharmaceutical and biotech industry, however, the picture is different. While AI is reshaping how work gets done, it has not, at least not yet, triggered widespread job losses in pharma. Instead, it’s changing what jobs look like, how work gets organized, and what skills matter most.

Why AI Fears Are So Visible – and Why They Don’t Tell the Full Story

AI’s potential impact on jobs has dominated headlines for good reason: automation tools can handle tasks once done by humans, and some large organizations have linked layoffs to AI initiatives. For example, Amazon recently announced the elimination of roughly 16,000 roles, partly suggesting that generative AI tools will allow smaller teams to do more with less.

But the relationship between AI and job losses isn’t straightforward. Economists and labor researchers point out that only a small fraction of recent layoffs can actually be tied directly to AI automation. Many job cuts may stem more from economic conditions, reorganizations, or other strategic decisions rather than pure automation.

AI often acts as a productivity tool, helping people do work faster, not necessarily eliminating the need for people altogether.

This nuance matters because the fear of AI wiping out millions of jobs may be overstated if taken at face value, at least for now. But even if AI isn’t directly replacing workers, it is reshaping job responsibilities, labor markets, and future career pathways across sectors.

The Current Job Landscape in Pharma: Resilience Instead of Reductions

Despite a wave of AI-related layoffs elsewhere, the pharmaceutical and biotech industries are not currently experiencing widespread replacement of human workers due to AI. Industry recruiters and C-suite leaders alike say AI is transforming roles rather than eliminating them one-for-one.

According to Jae Yoo, executive director of EPM Scientific, a firm specializing in life science hiring, pharma is seeing “rehousing and reshaping” of roles rather than direct displacement. That is, AI is influencing job content but not wholesale removal of positions.

A recent internal poll of pharma executives echoes this perspective: many do not believe AI will lead to significant layoffs in the industry. Instead, leaders at companies like Pfizer have described AI as something that elevates and expands work rather than simply replacing human effort.

In fact, some major pharmaceutical companies are actively hiring more talent because of AI initiatives, particularly in scientific and technical areas. For example, Eli Lilly and its collaboration with NVIDIA to build an “AI factory for drug discovery” is creating new scientific and analytical roles rather than downsizing.

Reshaping Roles: Hybrid Skills Are the New Norm

One of the clearest effects of AI in pharma isn’t job loss, but job transformation. The boundary between functions, like analytics, commercial strategy, and market access, is blurring, and companies are increasingly seeking hybrid skill sets that combine life sciences expertise with data fluency.

Rather than replacing roles, AI tools are automating routine, rules-based tasks, and companies are restructuring work to focus human talent on areas where judgment, creativity, and scientific insight matter most. As Yoo put it, pharma’s talent needs are shifting toward positions that leverage AI to augment human decision-making, not replace it.

In practical terms, this means rising demand for:

• AI and machine learning engineers who can apply advanced models to drug discovery and data analysis.

• Commercial analytics professionals capable of translating real-world evidence into market insights.

• Cross-functional specialists who can bridge scientific, regulatory, and technical domains.

These hybrid roles reflect the industry’s increasing reliance on data-driven decision-making while recognizing that science and strategy still require human expertise.

Where AI Skills Are Most Needed in Pharma

The areas where AI is creating the most opportunity in pharma reveal how the industry views the technology, as a complement to human talent rather than a replacement for it. Some of the highest-demand roles include:

Drug Discovery and Preclinical Research: AI’s ability to process vast datasets and identify patterns accelerates early stages of drug design, target discovery, and lead optimization. Companies are building in-house AI discovery teams rather than outsourcing or eliminating research roles. This means a growing need for professionals who understand both biological sciences and computational methods, a blend of expertise that bridges lab science and algorithmic analysis.

Commercial Analytics and Market Strategy: As data becomes more central to understanding patients, prescribers, and market dynamics, roles that combine analytics with commercial insight are booming. Pharma organizations want people who can interpret AI-driven signals and translate them into actionable strategies for product launch, pricing, access, and patient engagement.

Regulatory and Time-to-Market Support: Regulatory success remains a critical source of value in pharma. Professionals who can integrate AI with traditional regulatory science to streamline submissions, improve evidence generation, and anticipate compliance challenges, are increasingly in demand.

AI as a Force for Upskilling, Not Downsizing

The industry’s leadership consensus suggests that curiosity, creativity, and critical thinking are the attributes most likely to retain value in the AI era. Learning how to work alongside AI, not compete with it, is becoming a core professional imperative.

This means pharma companies should:

• Invest in ongoing upskilling and reskilling programs to help employees adapt to AI-augmented workflows.

• Emphasize interdisciplinary training that blends science with data literacy, ethics, and digital fluency.

• Position AI not as an efficiency threat, but as a tool that expands human capability and accelerates impact.

Leaders who manage this transition well can foster cultures where technology enhances human potential, rather than threatening livelihoods.

Will Pharma Eventually See AI-Driven Job Losses?

It’s impossible to fully predict the future, and some analysts warn that AI could affect pharma jobs over the long term. But several factors differentiate pharma from sectors where job displacement has already begun to show up more clearly:

Pharma’s mission focus on developing therapies and improving patient outcomes puts scientific discovery and clinical decision-making at the heart of its value creation, areas that are harder to automate completely.

Regulatory complexity, life sciences work is deeply governed by regulatory science, where human judgment and accountability remain essential.

High skill intensity, the industry already requires advanced expertise, making automation of core functions less straightforward.

For now, the consensus among pharma executives and recruitment specialists is that AI will reshape roles and demand new skills but not eliminate them outright.

Sum Up

The debate over AI and job losses can easily veer into fear or hype. But in the pharmaceutical industry, where complexity, regulation, and mission priorities differ from other sectors, the narrative is more nuanced – AI isn’t slashing jobs in pharma; it’s reshaping them.

Rather than displacing talent, AI is creating new opportunities, demanding hybrid skills, and accelerating innovation. For leaders, the challenge is not to resist AI, but to guide its adoption in ways that preserve human judgment, encourage professional growth, and enhance organizational impact.

In this dynamic era, the future of work in pharma will be defined not by machines versus humans, but by how well humans use machines to solve the world’s most pressing health challenges.

Concluded.

Disclaimers: Pictures in these blogs are taken from free resources at Pexels, Pixabay, Unsplash, and Google. Credit is given where available. If a copyright claim is lodged, we shall remove the picture with appropriate regrets.

For most blogs, I research from several sources which are open to public. Their links are mentioned under references. There is no intent to infringe upon anyone’s copyrights. If, any claim is lodged, it will be acknowledged and duly recognized immediately.

Reference:

https://www.pharmavoice.com/news/ai-job-losses-amazon-nvidia-pharma-drug/812381/